Breaking News

Seattle Genetics Expands AbbVie ADC Pact

By Kristin Brooks | January 8, 2014

AbbVie gains additional rights to Seattle Genetics technology

Seattle Genetics has expanded its antibody-drug conjugate (ADC) collaboration with AbbVie, under which AbbVie will pay $25 million upfront for additional rights to use Seattle Genetics’ ADC technology against AbbVie oncology targets, including Seattle Genetics’ pyrrolobenzodiazepine (PBD) dimer ADC technology and EC-mAb site-specific conjugation technology. Seattle Genetics is eligible to receive as much as $255 million in potential license fees and development and commercial milestones per target, as well as royalties on sales of any resulting products.
“Seattle Genetics continues to advance the field of ADCs through the development and optimization of innovative approaches to empowering antibodies, such as our proprietary EC-mAb and potent PBD-based ADC technologies, both of which are utilized in our pipeline programs SGN-CD33A and SGN-CD70A,” said Natasha Hernday, vice president, corporate development at Seattle Genetics. “By collaborating with companies such as AbbVie, we are expanding the reach of our ADC technology advancements to make novel targeted therapies available for cancer patients.”
The original collaboration began with an upfront payment of $8 million in March 2011 under an ADC deal with Abbott, prior to the spinoff of AbbVie. In October 2012, AbbVie paid an additional $25 million to expand the collaboration. AbbVie is responsible for research, development, manufacture, and commercialization of any ADC products resulting from the collaboration. 

Related Contract Manufacturing: